Jazz Pharmaceuticals expands revolver to $885M, extends maturity to 2029

Jazz Pharmaceuticals plc

Revolving credit facility increased from $500M to $885M; maturity extended from May 2026 to Nov 2029.
Initial applicable margin reduced by 125 bps: Term SOFR +2.00% and prime +1.00%.
Facility was undrawn as of Nov 26, 2024; financial covenants apply only when drawn.
Springing maturity provisions tied to 2026 exchangeable notes and 2028 term loan thresholds.
Amendment adds new lenders and commits to customary conditions for effectiveness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.